Flow cytometry was used to analyse the DNA content of 20 unfixed prostatic specimens obtained from patients with cancer of the prostate. The tumours were of different stages and grades of differentiation and the numbers of cells in each phase of the cell cycle were compared to those obtained from 26 patients with benign prostatic hyperplasia. It was noted that, as the cancer progressed from a well to a poorly differentiated state, there was a distinct shift in the distribution of cells in the G₀/G1 phase towards the S and G2+M phases. This was particularly marked in cases with a summed Gleason score of 7–10, and was independent of the stage and bulk of the tumour. Furthermore, all tumours with a Gleason score of 7 or more exhibited a tetraploid histogram, whereas only 2 of 14 patients with a well or moderately well differentiated cancer had tetraploid histograms. Two patients were found to have tumours with aneuploid DNA content, and both died within 2 years from the time of diagnosis. Although it is too early to speculate on the place flow cytometry in the clinical management of patients with cancer of the prostate, the results generated from this present study suggest that flow cytometry may be capable of providing prognostic information not supplied from histopathological analysis.

Keywords:
DNA, Prostate, Benign prostatic hyperplasia, Cancer, stage and grade, Flow cytometry
This content is only available via PDF.
© 1989 S. Karger AG, Basel
1989
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.